Detalhe da pesquisa
1.
Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma.
Cancer Immunol Immunother
; 73(2): 28, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38280045
2.
Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
BMC Cancer
; 24(1): 632, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38783238
3.
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
Ann Oncol
; 34(4): 420-430, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36681299
4.
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections.
Cancer Immunol Immunother
; 72(11): 3475-3489, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37606856
5.
Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
Qual Life Res
; 32(9): 2517-2525, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37079262
6.
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Ann Oncol
; 33(2): 204-215, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34710571
7.
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
Ann Oncol
; 33(9): 968-980, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35716907
8.
Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
BMC Cancer
; 22(1): 1366, 2022 Dec 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36585700
9.
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Ann Oncol
; 32(7): 917-925, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798657
10.
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma.
Ann Oncol
; 32(6): 766-777, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33744385
11.
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.
Acta Oncol
; 60(1): 69-77, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32924708
12.
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.
Ann Oncol
; 31(1): 144-152, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31912789
13.
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapyâ.
Ann Oncol
; 31(8): 1075-1082, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32387454
14.
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.
Ann Oncol
; 31(11): 1449-1461, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32763452
15.
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.
Ann Oncol
; 31(11): 1435-1448, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32763453
16.
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
Ann Oncol
; 30(7): 1154-1161, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923820
17.
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.
Ann Oncol
; 30(6): 998-1004, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30895304
18.
Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma.
Br J Surg
; 106(5): 519-522, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30882901
19.
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
Ann Oncol
; 29(8): 1861-1868, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945191
20.
Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience.
Ann Oncol
; 28(4): 862-867, 2017 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28158487